Isabel D. Markl, Ph.D.
Affiliations: | 2006 | University of Southern California, Los Angeles, CA, United States |
Area:
DNA methylation, cancer, epigeneticsGoogle:
"Isabel Markl"Mean distance: 14248.8
Parents
Sign in to add mentor| Peter A. Jones | grad student | 2006 | USC | |
| (In vivo and in vitro analysis of the epigenetic and genetic alterations in the progression of human bladder cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Markl ID, Cheng J, Liang G, et al. (2001) Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Research. 61: 5875-84 |
| Tsao JL, Yatabe Y, Markl ID, et al. (2000) Bladder cancer genotype stability during clinical progression. Genes, Chromosomes & Cancer. 29: 26-32 |
| Salem CE, Markl ID, Bender CM, et al. (2000) PAX6 methylation and ectopic expression in human tumor cells. International Journal of Cancer. Journal International Du Cancer. 87: 179-85 |
| Markl ID, Jones PA. (1998) Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Research. 58: 5348-53 |
| Walker GJ, Flores JF, Glendening JM, et al. (1998) Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes, Chromosomes & Cancer. 22: 157-63 |